Atenolol Market Trends

  • Report ID: 4076
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Atenolol Market Trends

Growth Drivers

  • Growing Prevalence of Angina Experiences - Angina is a type of chest pain that occurs by a decrease in blood flow to the heart. It is mainly caused by an accumulation of fatty deposits in the arteries supplying blood to the heart muscles. In such a condition, the heart beats faster and a person feels a sharp pain and pressure in his/her chest. It is an early sign of heart disorders. Atenolol belongs to a class of drugs referred to as beta blockers. Beta-blockers decrease the oxygen demand of the heart and lower the occurrence of angina attacks by reducing heart rate. Hence, the increasing prevalence of angina attacks is estimated to expand market growth further over the projected time frame. For instance, in the United States, each year angina affects more than 9 million people.
  • Expansion in Sedentary Lifestyle - Physical inactivity can have major adverse health effects. An inactive lifestyle raises the risk of all causes that result in death and doubles the chance of a variety of conditions such as cardiovascular disease, diabetes, obesity, anxiety, and so on. Therefore, an increase in sedentary lifestyles is also projected to drive the growth of the atenolol market in the coming years. As reported by the World Health Organization, 27% of adults and more than 80% of adolescents globally fail to comply with the recommended physical activity ratio.
  • Increasing Prevalence of Arrhythmia - Any issue with a person's heartbeat rate or rhythm is referred to as an "arrhythmia." Electrical waves that are too fast, too slow, or chaotic during an arrhythmia can cause an irregular heartbeat. The heart cannot properly pump blood when it is not beating appropriately. The lungs, brain, and all the other organs are unable to function properly and may get damaged. Atenolol helps in this situation by lowering your heart rate, which makes it easier for your heart to circulate blood throughout the organs. Thus, the rising prevalence of arrhythmia is also estimated to boost the market growth of atenolol over the forecast period. As per an estimation, Arrhythmia is anticipated to affect approximately 1.7% to 6% of the overall population in the United States.
  • Rise in Poor Dietary Habits - According to a new worldwide study conducted in 2021, approximately 50% of the global population suffers from poor dietary habits, which has negative consequences for people.
  • Rising Cases of Cardiovascular Disorders – Based on the World Health Organization figures, cardiovascular diseases are the most prevalent cause of death throughout the world, claiming the lives of an estimated 17.9 million people annually.

Challenges

  • Associated Side Effects of Atenolol – Though atenolol helps to tackle several kinds of hypertension issues still numerous side effects are associated with the use of atenolol comprising feeling sleepiness, dizziness, nausea, hypotension, blurred vision, bloody urination, and so on. Hence, this factor is anticipated to dampen the growth of the market in the coming years.
  • Availability of Diuretics and Other Drugs
  • Risk of Interaction with Other Drugs

Atenolol Market: Key Insights

Global Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.  

Base Year

2024

Forecast Year

2025-2037

CAGR

5.5%

Base Year Market Size (2024)

USD 12.23 billion

Forecast Year Market Size (2037)

USD 12.23 billion

Regional Synopsis

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4076
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.

The atenolol market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia will boost the market growth.

North America industry is set to hold largest revenue share of 40% by 2037, attributed to increasing prevalence of cardiac diseases, along with rising frequency of hypertension in the region.

The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals (USA) Inc., Ipca Laboratories Limited, Unichem Laboratories Limited, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample